Composition, form of production and packaging
Lyophilizate for the preparation of a solution for the / m introduction in the form of a white porous mass, packed into a tablet, odorless.
1 amp.
chondroitin sulfate 100 mg
100 mg - ampoules (5) complete with a solvent (water d / and 1 ml - amp 5 pcs.) - packs cardboard.
100 mg - ampoules (10) complete with a solvent (water d / and 1 ml - amp 10 pcs.) - packs of cardboard.
100 mg - ampoules (10) - packs of cardboard.
100 mg - ampoules (10) - contour plastic packaging (1) - cardboard packs.
100 mg - ampoules (10) - contour plastic packaging (2) - cardboard packs.
100 mg - ampoules (10) - packings contour plastic (4) - packs cardboard.
100 mg - ampoules (5) - contour plastic packaging (1) - cardboard packs.
100 mg - ampoules (5) - packings contour plastic (2) - packs cardboard.
100 mg - ampoules (5) - packings contour plastic (4) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Chondroitin sulfate is the main component of proteoglycans that make up the cartilaginous matrix together with collagen fibers. Has chondroprotective properties;inhibits the activity of enzymes that cause degradation of the articular cartilage; stimulates the production of proteoglycans by chondrocytes; strengthens metabolic processes in cartilage and subchondral bone; participates in the construction of the main substance of bone and cartilaginous tissue. It has an anti-inflammatory and analgesic effect, helps to reduce the release of inflammatory mediators and pain factors into the synovial fluid through synovial and macrophage synovial membranes, inhibits the secretion of leukotriene B 4 and prostaglandin E 2 .
The drug contributes to the restoration of the cartilaginous surfaces of the joints, prevents the collapse of connective tissue; normalizes the production of articular fluid, which leads to better mobility of joints, reducing pain intensity.
PHARMACOKINETICS
Chondrolon is easily absorbed when administered intramuscularly. The maximum concentration is achieved 1 hour after the administration.
The drug accumulates in the synovial fluid. It is excreted from the body mainly by the kidneys within 24 hours.
INDICATIONS
osteoarthrosis of peripheral joints and spine.
DOSING MODE
Enter intramuscularly for 100 mg (1 ampoule) every other day. Before use, the contents of the ampoule are dissolved in 1 ml of water for injection. With good tolerability, the dose is increased to 200 mg (2 ampoules), starting with the fourth injection. The course of treatment is 25-35 injections. Repeated courses - after 6 months.
The duration of repeated courses of treatment is set by the doctor.
To achieve a stable clinical effect, at least 25 injections of chondrolon are necessary, with the effect remaining long after the end of the second course of treatment.
The experience of the drug in children is not.
SIDE EFFECT
Allergic reactions, hemorrhages at the injection site.
CONTRAINDICATIONS
- Hypersensitivity to chondroitin sulfate;
- tendency to bleeding;
- thrombophlebitis;
- Pregnancy;
- the period of breastfeeding (at the time of treatment, breast-feeding should be discontinued).
PREGNANCY AND LACTATION
Contraindicated in lactation and in the period of lactation.
APPLICATION FOR CHILDREN
The experience of the drug in children is not.
DRUG INTERACTION
Chondrolon may increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents, which requires more frequent monitoring of blood coagulation indicators when combined with the use of drugs.
TERMS OF RELEASE FROM PHARMACY
On prescription.
TERMS AND CONDITIONS OF STORAGE
In a dry place, protected from light, out of reach of children, at a temperature not exceeding 20 В° РЎ. Shelf life - 3 years.
